secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0000950170-23-057146
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara expands tab-cel partnership worth up to $640M, cuts workforce 30%, Q3 loss $69.8M
--------------------------------------------------------------------------------

- Expanded global tab-cel deal with Pierre Fabre: up to $640M in payments, ~$30M upfront and $100M regulatory milestones, plus tiered double-digit royalties.
- Workforce reduction of ~30% to extend cash runway into Q3 2025; $7M in severance charges expected.
- Q3 net loss $69.8M ($0.66/sh) vs $84.1M ($0.82/sh) in prior year; cash, equivalents, and investments $102.4M at Sep 30.
- ATA188 Phase 2 EMBOLD primary analysis on track for early Nov; focus shifts to ATA188 and AlloCAR-T programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/0000950170-23-057146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017023057146/atra-20231031.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-057146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer